The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST).

Andrew J.  Wagner

Consulting or Advisory Role - Five Prime Therapeutics; Lilly; Loxo

Research Funding - AADi (Inst); Celldex (Inst); Daiichi Sankyo (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst)

William D.  Tap

Consulting or Advisory Role - Adaptimmune; Blueprint Medicines; Daiichi Sankyo; Eisai; EMD Serono; Immune Design; Janssen; Lilly; Loxo; Novartis; Plexxikon; TRACON Pharma

Anthony Frank  Shields

Employment - Benchling (I)

Stock and Other Ownership Interests  - Benchling (I)

Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Endocyte; GE Healthcare; Merck; Merrimack; Personal Genome Diagnostics; Siemens Healthcare Diagnostics; Taiho Pharmaceutical

Speakers' Bureau - GE Healthcare

Research Funding - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Caris Life Sciences; Eisai; H3 Biomedicine; Inovio Pharmaceuticals; Karyopharm Therapeutics; Merrimack; Novartis; OncoMed; Plexxikon; Taiho Pharmaceutical

Travel, Accommodations, Expenses - Caris Life Sciences; Endocyte; GE Healthcare; Merrimack

Amita  Patnaik

Consulting or Advisory Role - Bayer

Research Funding - Abbvie; Aeglea Biotherapeutics; Alexion Pharmaceuticals; Amgen; Asana Biosciences; Ascentage Pharma Group; Astex Pharmaceuticals; AVEO (Inst); Bayer; Bayer (Inst); Calithera Biosciences; Celgene (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Endocyte (Inst); Five Prime Therapeutics (Inst); Formation Biologics (Inst); Forty Seven; Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jiangsu Hengrui Medicine; Jiangsu Hengrui Medicine (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Merck Sharp & Dohme; Novartis; OncoMed; Pfizer (Inst); Plexxikon; Plexxikon (Inst); Regeneron (Inst); Symphony Evolution (Inst); TaiRx, Inc. (Inst); Tesaro (Inst); Tesaro (Inst); Teva (Inst); Upsher-Smith; Zymeworks (Inst)

Rashmi  Chugh

Stock and Other Ownership Interests  - Portola Pharmaceuticals

Consulting or Advisory Role - EMD Serono; Epizyme; Janssen

Research Funding - AADi (Inst); Advenchen Laboratories (Inst); Biomarin (Inst); Epizyme (Inst); Lilly (Inst); MabVax (Inst); Morphotek (Inst); Novartis (Inst); Pfizer (Inst)

Gabriel  Tinoco

No Relationships to Disclose

Glenn  Michelson

Employment - Plexxikon

Oscar  Alcantar

Employment - Plexxikon

Michael  Pelayo

Employment - Plexxikon

Stock and Other Ownership Interests  - Plexxikon

Chao  Zhang

Employment - Plexxikon

Paul  Severson

Employment - Plexxikon

Eric  Martin

Employment - Plexxikon

Jonathan C.  Trent

Honoraria - GlaxoSmithKline

Consulting or Advisory Role - Janssen; Lilly; Novartis